Movement Alert｜SELLAS Life Sciences Group Inc. Falls 8.63% in Regular Trading, All Arbitration Claims Dismissed

Market Focus07-28

On July 28, SELLAS Life Sciences Group Inc. fell 8.63% in regular trading, trading at $9.505/share, with turnover of $30.53 million.

On the news front, 3D Medicines announced that the arbitration case with SELLAS Life Sciences at the Hong Kong International Arbitration Centre has received a final ruling, with all claims filed by SELLAS being fully dismissed. SELLAS is also required to bear the opposing party's arbitration-related expenses totaling HK$7.983 million, payable by August 7.

Meanwhile, 3D Medicines stated it will continue to advance the development and commercialization of Galinpepimut-S (GPS) in the Greater China region. The arbitration loss means SELLAS's disputed claims regarding the regional collaboration were not upheld, while the company faces additional expense obligations, weighing on market sentiment. SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies, with GPS targeting acute myeloid leukemia currently in Phase 3 trials.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1101501712?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-28 22:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1101501712","market":"hk","top_or_hot":-1,"title":"Movement Alert｜SELLAS Life Sciences Group Inc. Falls 8.63% in Regular Trading, All Arbitration Claims Dismissed","media":"Market Focus","content":"<p><p>On July 28, SELLAS Life Sciences Group Inc. fell 8.63% in regular trading, trading at $9.505/share, with turnover of $30.53 million.</p><p>On the news front, 3D Medicines announced that the arbitration case with SELLAS Life Sciences at the Hong Kong International Arbitration Centre has received a final ruling, with all claims filed by SELLAS being fully dismissed. SELLAS is also required to bear the opposing party's arbitration-related expenses totaling HK$7.983 million, payable by August 7.</p><p>Meanwhile, 3D Medicines stated it will continue to advance the development and commercialization of Galinpepimut-S (GPS) in the Greater China region. The arbitration loss means SELLAS's disputed claims regarding the regional collaboration were not upheld, while the company faces additional expense obligations, weighing on market sentiment. SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies, with GPS targeting acute myeloid leukemia currently in Phase 3 trials.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜SELLAS Life Sciences Group Inc. Falls 8.63% in Regular Trading, All Arbitration Claims Dismissed</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜SELLAS Life Sciences Group Inc. Falls 8.63% in Regular Trading, All Arbitration Claims Dismissed\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-28 22:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 28, SELLAS Life Sciences Group Inc. fell 8.63% in regular trading, trading at $9.505/share, with turnover of $30.53 million.</p><p>On the news front, 3D Medicines announced that the arbitration case with SELLAS Life Sciences at the Hong Kong International Arbitration Centre has received a final ruling, with all claims filed by SELLAS being fully dismissed. SELLAS is also required to bear the opposing party's arbitration-related expenses totaling HK$7.983 million, payable by August 7.</p><p>Meanwhile, 3D Medicines stated it will continue to advance the development and commercialization of Galinpepimut-S (GPS) in the Greater China region. The arbitration loss means SELLAS's disputed claims regarding the regional collaboration were not upheld, while the company faces additional expense obligations, weighing on market sentiment. SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies, with GPS targeting acute myeloid leukemia currently in Phase 3 trials.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SLS","symbol_name":"SELLAS Life Sciences Group Inc.","start_time":0,"source_url":"","article_id":"1101501712","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1101501712","pubTimestamp":1785248392,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 28, SELLAS Life Sciences Group Inc. fell 8.63% in regular trading, trading at $9.505/share, with turnover of $30.53 million.On the news front, 3D Medicines announced that the arbitration case...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SLS":"SELLAS Life Sciences Group Inc."},"translate_title":"走势警报|SELLAS Life Sciences Group Inc. 常规交易下跌 8.63%，所有仲裁索赔均被驳回","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLS":1},"content_text":"On July 28, SELLAS Life Sciences Group Inc. fell 8.63% in regular trading, trading at $9.505/share, with turnover of $30.53 million.On the news front, 3D Medicines announced that the arbitration case with SELLAS Life Sciences at the Hong Kong International Arbitration Centre has received a final ruling, with all claims filed by SELLAS being fully dismissed. SELLAS is also required to bear the opposing party's arbitration-related expenses totaling HK$7.983 million, payable by August 7.Meanwhile, 3D Medicines stated it will continue to advance the development and commercialization of Galinpepimut-S (GPS) in the Greater China region. The arbitration loss means SELLAS's disputed claims regarding the regional collaboration were not upheld, while the company faces additional expense obligations, weighing on market sentiment. SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies, with GPS targeting acute myeloid leukemia currently in Phase 3 trials.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1101501712","isCrawlerRequest":true}